TITLE:
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

CONDITION:
Prostatic Neoplasms

INTERVENTION:
Atrasentan

SUMMARY:

      This study is being done to evaluate the safety and efficacy of atrasentan in men with
      non-metastatic hormone-refractory prostate cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 19 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Have been diagnosed with prostate cancer.

          -  Have a rising PSA while on hormone therapy or following surgical castration.

        Exclusion Criteria:

          -  Have evidence of distant metastatic disease on screening bone scan or CT scan.

          -  Have received cytotoxic chemotherapy.

          -  Have received opioid or narcotic medications (such as codeine or morphine) or
             radiation for pain caused by your prostate cancer in the last 6 months.
      
